π How Vaccines Are Made
From lab bench to vial: the 10-15 year pipeline.
Typical development timeline
For informational purposes only, not medical advice.
A typical vaccine takes 10 to 15 years from first research to licensure: exploratory science, preclinical testing, three phases of clinical trials, regulatory review, and manufacturing scale-up, each with failure points. Starting in 2020, a conventional timeline reaches licensure around 2032. Understanding the pipeline explains both why vaccines normally take so long and how COVID vaccines moved faster without skipping the safety steps that matter.
The pipeline is a filter, not a conveyor: most candidates fail, usually in phase 2 or 3, which is why the decade-plus timeline and billion-dollar cost are features of a system that demands proof, not bugs in it.
How to Explore the Pipeline
Enter a development start year. The tool lays out each stage with typical durations and the calendar years they would land in.
Enter the year research began.
Read the stage table: durations, cumulative timeline, and projected years.
Note which stages run in parallel in emergencies and which never get skipped.
The Stages
Exploratory research identifies antigens and concepts; preclinical tests them in cells and animals for immune response and toxicity. Phase 1 gives the candidate to dozens of healthy volunteers for safety; phase 2 to hundreds for dosing and immune response; phase 3 to tens of thousands for efficacy against real disease. Regulators then review the complete dossier while manufacturing scales under strict quality control.
Manufacturing deserves emphasis: vaccines are biologics, grown in cells or eggs under exacting conditions, with batch testing that can take months per lot. The factory is part of the product; regulators approve the process, not just the molecule.
Worked Example
Start 2020 on a conventional timeline: exploratory through ~2022, preclinical to ~2024, phase 1 to ~2025, phase 2 to ~2027, phase 3 to ~2031, review to ~2032. Thirteen years, most of it in trials, which matches the historical average.
COVID mRNA vaccines compressed this to under a year from sequence to authorization by running stages in parallel, building on decades of mRNA and coronavirus research, and manufacturing at risk before results. The phases still happened, with tens of thousands in trials; the waiting between them did not.
Vaccine Types
| Platform | How it works | Examples |
|---|---|---|
| mRNA | Instructs cells to make the antigen briefly. | COVID-19 vaccines |
| Viral vector | Harmless virus delivers antigen instructions. | Ebola, some COVID vaccines |
| Protein subunit | Delivers the antigen protein directly. | Hepatitis B, HPV, shingles |
| Inactivated | Killed pathogen trains the immune system. | Polio (IPV), flu shots |
| Live-attenuated | Weakened pathogen, strong lasting immunity. | MMR, chickenpox |
My take: platform knowledge pays off when new vaccines arrive, because the safety questions differ by type. Live vaccines concern the immunocompromised; mRNA concerns were about the novelty of the platform, answered by the largest safety datasets in history.
Limits
Timelines are typical ranges; individual vaccines vary widely, and the table simplifies regulatory differences across countries. It also omits post-marketing surveillance, the phase 4 monitoring that continues for years after licensure and has caught rare safety signals.
Related Tools
Understand trial results with the vaccine efficacy calculator and protection length with our vaccine immunity guide.
For informational purposes only, not medical advice. Consult a healthcare professional.
Frequently Asked Questions
How long does it take to make a vaccine?
Typically 10-15 years from initial research to licensure, most of it in clinical trials. COVID-19 mRNA vaccines were developed in under a year through parallel stages, prior research, and at-risk manufacturing, without skipping trial phases.
What are the phases of vaccine trials?
Phase 1 tests safety in dozens of volunteers, phase 2 tests dosing and immune response in hundreds, and phase 3 tests efficacy in tens of thousands. Each phase must succeed before the next begins, conventionally.
Were COVID vaccines rushed?
The phases were not skipped: tens of thousands participated in trials with standard safety follow-up. Speed came from overlapping stages, massive funding, prior mRNA and coronavirus research, and manufacturing before approval.
How are vaccines manufactured?
As biologics grown in cell cultures or eggs under strict sterile conditions, then purified, formulated, and batch-tested, a process regulators approve alongside the vaccine itself. Quality control per batch can take months.
What is the difference between vaccine types?
mRNA and viral vectors instruct your cells to make the antigen; protein subunit delivers it directly; inactivated uses killed pathogen; live-attenuated uses weakened pathogen. Each has different storage, dosing, and safety profiles.
Why do most vaccine candidates fail?
Usually lack of efficacy or safety signals in phase 2/3 trials. The pipeline is designed to filter: only candidates that prove safe and effective in large trials reach licensure.
What is phase 4?
Post-marketing surveillance after licensure: ongoing monitoring for rare side effects in millions of recipients through systems like VAERS and the Vaccine Safety Datalink. It has detected very rare signals missed by trials.
Who approves vaccines?
In the US, the FDA licenses vaccines after reviewing trial data, advised by VRBPAC, with CDC's ACIP setting usage recommendations. Other countries have their own regulators using similar evidence standards.
Can manufacturing affect safety?
Yes, which is why regulators approve the manufacturing process itself and require batch testing. Contamination or process drift would be caught by the quality systems before distribution.
Where can I read official development data?
FDA review documents, published trial papers, and CDC/WHO backgrounders detail each licensed vaccine's development. This page teaches the pipeline shape; those sources hold the verified specifics.